Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.
Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
- Associated Therapies
- -
Treatment of ppROM With Erythromycin vs. Azithromycin Trial
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-06-25
- Target Recruit Count
- 21
- Registration Number
- NCT03060473
- Locations
- 🇺🇸
St. David's North Austin Medical Center, Austin, Texas, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- St. Justine's Hospital
- Target Recruit Count
- 1370
- Registration Number
- NCT03031210
- Locations
- 🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- University of Bamenda
- Target Recruit Count
- 300
- Registration Number
- NCT02974348
- Locations
- 🇨🇲
CDC Hospital, Tiko, South west, Cameroon
Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2021-12-28
- Target Recruit Count
- 46
- Registration Number
- NCT02969928
- Locations
- 🇧🇷
College of Dentistry - São José dos Campos, Sao Paulo State University, São José dos Campos, SP, Brazil
Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 382
- Registration Number
- NCT02935010
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Zhongshan Hospital,Fudan University, Shanghai, Shanghai, China
🇨🇳Shanghai Tenth People's Hospital, Tongji University, Shanghai, Shanghai, China
Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- University of Oulu
- Target Recruit Count
- 73
- Registration Number
- NCT02935374
- Locations
- 🇫🇮
Mehiläinen, private practice, Oulu, Finland
TAK-438 Bismuth Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT02892409
Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2021-02-03
- Target Recruit Count
- 385
- Registration Number
- NCT02891915
- Locations
- 🇺🇸
University of Alabama - Children's of Alabama - Infectious Diseases/Virology, Birmingham, Alabama, United States
🇺🇸University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, United States
🇺🇸Washington University School of Medicine in St. Louis - Infectious Diseases, Saint Louis, Missouri, United States
Changes in Resistome After Dental Extraction and Amoxicillin.
- Conditions
- Interventions
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 16
- Registration Number
- NCT02830347
- Locations
- 🇨🇳
Oral Rehabilitation, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China
An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures
- Conditions
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- University of Santiago de Compostela
- Target Recruit Count
- 40
- Registration Number
- NCT02783404
- Locations
- 🇪🇸
Hospital Clinico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain
🇪🇸Santiago de Compostela University Hospital, Santiago de Compostela, Coruña, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.